Select Treatment Strategy
Compare treatment pathways by response, escalation, time to response, cost, and modeled value.
Preferred strategy
Upfront IV iron
Total cost
$18.35M
Responders
8,740
Non-responders
1,260
Escalations
50
Adverse events
600
Cost per responder
$2,099
ICER vs comparator
$31,930 / QALY
Results table
| Strategy | Responders | Escalations | AEs | Total cost | QALYs | NMB | ICER | TTR (wks) | Decision |
|---|---|---|---|---|---|---|---|---|---|
| Watchful waiting / usual care | 1,200 | 1,760 | 100 | $3.70M | -118.00 | -$15.50M | Dominant (lower cost, higher QALYs) | 16 | Dominated |
| Oral iron daily | 3,472 | 1,828 | 2,200 | $5.55M | -0.96 | -$5.65M | Dominant (lower cost, higher QALYs) | 8 | Dominated |
| Oral iron alternate-day | 4,752 | 1,050 | 1,400 | $4.06M | 104.64 | $6.40M | $-14,126 / QALY | 10 | Requires review |
| Step-up therapy (oral, then IV) | 6,020 | 1,194 | 1,600 | $5.15M | 189.40 | $13.79M | $-2,104 / QALY | 6 | Requires review |
| Upfront IV iron | 8,740 | 50 | 600 | $18.35M | 399.80 | $21.63M | $31,930 / QALY | 3 | Preferred |
Responders by strategy
Total cost by strategy
Cost per responder
Time to response (weeks)
Cost vs QALYs
Net monetary benefit
Treatment pathway flow — Upfront IV iron
Cohort
10,000
Initial treatment
10,000
Responders
8,740
Escalated to IV
50
Adverse events
600
Interpretation
At the selected assumptions for General US adults (Mild IDA), Upfront IV iron produces the highest net monetary benefit. This reflects a balance between treatment cost, response rate (87%), escalation burden, and adverse-event management. IV iron acquisition cost threshold for upfront IV to dominate step-up therapy in this scenario is approximately $1,630.
Results are generated from an illustrative demonstration model and should not be interpreted as final clinical, policy, or economic conclusions.